Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Several years ago, the PROWESS trial demonstrated a mortality benefit for drotrecogin alfa [activated] (DrotAA; APC) in patients with severe sepsis, and that this benefit was most pronounced in those at high risk of death (ie, APACHE score > 25 or multi-organ dysfunction).

APC for Lower-Risk Sepsis: Outcomes at One Year